Harrow pharmacy sale falls through

The leaders of ophthalmic care company Harrow Health have signed an agreement to buy the U.S. and Canadian rights to a proposed anesthetic designed to be used during cataract surgeries and other eye procedures.

Nashville-based Harrow will pay Switzerland-based Sintetica $5 million in the next month and is on the hook for up to another $13 million in payments related to regulatory and commercial milestones. Sintetica, which had about $100 million in revenue last year, will be responsible for the regulatory filings for AMP-100, a surface anesthetic candidate.

The possible market for AMP-100 is a big one: More than 10 million eye procedures in which it could be used are performed each year in the United States. Sintetica recently completed a Phase 3 study for its treatment and plans to submit its application with the the U.S. Food and Drug Administration late this year.

“The acquisition of rights to market and sell AMP-100 in the U.S. and Canada will further fortify our greatest commercial strength — providing thousands of U.S. eyecare professionals and their patients with novel ophthalmic surgical products,” Harrow CEO Mark Baum said in a statement Tuesday.

In addition to the milestone payments, Harrow will pay Sintetica royalties on sales of AMP100.

Shares of Harrow (Ticker: HROW) were up slightly Tuesday morning to $8.52. Year to date, they have risen about 15 percent, growing the company’s market capitalization to about $225 million.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.